☆ 4.6 Article

Ultrasensitive NGS MRD assessment in Ph plus ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1

AMERICAN JOURNAL OF HEMATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Ponatinib and blinatumomab for Philadelphia chromosome- positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour et al.

Summary: In this study, the researchers evaluated the combination of ponatinib and blinatumomab as a chemotherapy-free treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The results showed that this combination therapy achieved high rates of complete molecular response in patients with newly diagnosed and relapsed or refractory disease.

LANCET HAEMATOLOGY (2023)

添加到收藏夹

Article Oncology

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Elias Jabbour et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

Jayastu Senapati et al.

Summary: The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has been a model for cancer therapy development. Advances in understanding the disease transformation mechanisms have led to improved treatment and prognosis. Patients with previously treated CML-CP who transform to AP or BP should consider second- or third-generation TKIs and allogeneic stem cell transplantation. New combination therapies are expanding the treatment options for advanced phase CML.

LEUKEMIA (2023)

添加到收藏夹

Article Hematology

Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results

Hagop Kantarjian et al.

Summary: The combination of ponatinib and hyper-CVAD chemotherapy showed high rates of complete molecular remissions and survival in patients with Philadelphia chromosome-positive acute lymphocytic leukemia. Further studies with a larger cohort and longer follow-up are needed to establish this regimen as a new standard of care.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods

Michaela Kotrova et al.

Summary: Persistence of minimal residual disease (MRD) after induction/consolidation therapy in acute lymphoblastic leukemia is the leading cause of relapse. The GMALL 07/2003 study used MRD detection by real-time quantitative polymerase chain reaction of clonal immune gene rearrangements with 1 x 10(-4) as discriminating cutoff. The clinical relevance of MRD results not fitting into these categories is unclear and termed molecular not evaluable (MolNE). Within the study, patients with complete molecular response had better outcomes compared to those with molecular failure, and reanalysis using next-generation sequencing (NGS) further improved the classification of MolNE patients.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Nicholas J. Short et al.

Summary: This study evaluated the clinical impact of a highly sensitive next-generation sequencing (NGS) MRD assay in acute lymphoblastic leukemia (ALL) patients. The study found that NGS detection could identify patients with a significant risk of relapse, even if they were considered MRD negative by multiparameter flow cytometry (MFC). Early assessment of MRD using NGS provides important prognostic information for predicting relapse risk and long-term survival in ALL patients.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher

Elias J. Jabbour et al.

Summary: The presence of measurable residual disease (MRD) is the strongest predictor of relapse in acute lymphoblastic leukemia (ALL). Blinatumomab induced MRD negativity in most patients and resulted in high rates of relapse-free survival (RFS) and overall survival (OS).

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Armin Ghobadi et al.

Summary: Adult patients with Ph+ ALL who achieved CMR within 90 days of starting treatment did not derive a survival benefit from allo-HCT in CR1, according to this retrospective study.

BLOOD (2022)

添加到收藏夹

Article Oncology

Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease

Jan Zuna et al.

Summary: In this retrospective analysis, the prognostic relevance of minimal residual disease (MRD) and other features in BCR::ABL1-positive ALL were investigated. The study found that BCR::ABL1-positive ALL can be divided into typical ALL and CML-like subtype. The overall prognosis of typical ALL and CML-like patients was similar, but there were differences in relapse rates and mortality. MRD had a significant prognostic role in typical ALL, while it was not significant in CML-like patients. The study suggests that early distinguishing between typical BCR::ABL1-positive ALL and CML-like patients is important for optimal treatment approaches.

LEUKEMIA (2022)

添加到收藏夹

Meeting Abstract Hematology

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Emily C. Liang et al.

BLOOD (2022)

添加到收藏夹

Article Oncology

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

Michael A. Pulsipher et al.

Summary: We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to identify predictive biomarkers for relapse. The results showed that BMNGS-MRD 0 and B-cell recovery were independently associated with relapse, and detectable BMNGS-MRD reliably predicted the risk.

BLOOD CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

Koji Sasaki et al.

Summary: In patients with Ph-positive ALL, ponatinib is superior to other types of TKIs in inducing and maintaining a CMR, thus preventing disease progression. ASCT does not improve outcome once a 3-month CMR is achieved.

CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Robin Foa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Alejandro Medina et al.

BLOOD CANCER JOURNAL (2020)

添加到收藏夹

Article Hematology

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Philip A. Thompson et al.

BLOOD (2019)

添加到收藏夹

Review Hematology

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Nicholas J. Short et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Article Hematology

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Giovanni Cazzaniga et al.

HAEMATOLOGICA (2018)

添加到收藏夹

Article Hematology

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Giovanni Cazzaniga et al.

HAEMATOLOGICA (2018)

添加到收藏夹

Article Hematology

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Goekbuget et al.

BLOOD (2018)

添加到收藏夹

Article Hematology

Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL

Brent Wood et al.

BLOOD (2018)

添加到收藏夹

Article Oncology

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis

Donald A. Berry et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Hematology

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorkova et al.

BLOOD (2017)

添加到收藏夹

Article Hematology

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Nicholas J. Short et al.

BLOOD (2016)

添加到收藏夹

Review Oncology

The concept of treatment-free remission in chronic myeloid leukemia

S. Saussele et al.

LEUKEMIA (2016)

添加到收藏夹

Article Hematology

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Michael A. Pulsipher et al.

BLOOD (2015)

添加到收藏夹

Article Hematology

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Farhad Ravandi et al.

BLOOD (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.